News and analysis on disease research and diagnostics.
The drugmaker will present data from the Impower110 trial at an upcoming meeting and submit the data to regulatory authorities.
The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.
As labs implement TMB workflows in-house, studies are showing that its is possible to validate assays with cutoff points remaining stable across complex clinical cohorts and in different drug contexts.
Although the FDA has already approved the regimen in this indication after seeing its impact on progression-free survival, the latest data speaks to its impact on survival.
The companies will use their respective technologies to identify inhibitors of cancer-associated gene targets and optimize their use as therapeutics.
